| Basal cell carcinoma
Odomzo vs Erivedge
Side-by-side clinical, coverage, and cost comparison for basal cell carcinoma.Deep comparison between: Odomzo vs Erivedge with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsErivedge has a higher rate of injection site reactions vs Odomzo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Erivedge but not Odomzo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Odomzo
Erivedge
At A Glance
Oral
Daily
Hh pathway inhibitor
Oral
Daily
Hedgehog pathway inhibitor
Indications
- Basal cell carcinoma
- Metastatic basal cell carcinoma
- Basal cell carcinoma
Dosing
Basal cell carcinoma 200 mg orally once daily on an empty stomach, at least 1 hour before or 2 hours after a meal, until disease progression or unacceptable toxicity.
Metastatic basal cell carcinoma, Basal cell carcinoma 150 mg orally once daily, with or without food, until disease progression or unacceptable toxicity; swallow capsules whole.
Contraindications
—
—
Adverse Reactions
Most common (>=10%) Muscle spasms, alopecia, dysgeusia, fatigue, nausea, musculoskeletal pain, diarrhea, decreased weight, decreased appetite, myalgia, abdominal pain, headache, pain, vomiting, pruritus
Serious Musculoskeletal adverse reactions
Most common (>=10%) Muscle spasms, alopecia, dysgeusia, weight loss, fatigue, nausea, diarrhea, decreased appetite, constipation, arthralgias, vomiting, ageusia
Serious Embryo-fetal toxicity, severe cutaneous adverse reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), musculoskeletal adverse reactions, premature fusion of the epiphyses
Postmarketing Drug-induced liver injury, Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms
Pharmacology
Sonidegib is an Hh pathway inhibitor that binds to and inhibits Smoothened, a transmembrane protein involved in Hh signal transduction.
Vismodegib is an inhibitor of the Hedgehog pathway that binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Odomzo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Erivedge
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Odomzo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Erivedge
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Odomzo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Erivedge
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/momo
Odomzo Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Metastatic Skin Cancer - Non Melanoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OdomzoView full Odomzo profile
ErivedgeView full Erivedge profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.